Wedbush Reaffirms Outperform Rating for Replimune Group (NASDAQ:REPL)

Wedbush reissued their outperform rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $52.00 price objective on the stock. Wedbush also issued estimates for Replimune Group’s Q3 2024 earnings at ($0.90) EPS, FY2024 earnings at ($3.57) EPS, FY2025 earnings […]

Related Keywords

Pamela Esposito ,Analyst Recommendations For Replimune Group ,Blackrock Inc ,Replimune Group Inc ,Replimune Group ,Vanguard Group Inc ,Pricet Rowe Associates Inc ,Replimune Group Company Profile ,Replimune Group Stock Performance ,News Ratings For Replimune Group Daily ,Free Report ,Get Free Report ,Street Corp ,Vanguard Group ,Replimune Group Daily ,Nasdaq Repl ,Trepl ,Medical ,Reiterated Rating ,Wedbush ,